CDAK Stock : Codiak BioSciences Inc ( CDAK) shares are down -91.17 percent in the past 12 months. The average rating of Wall Street analysts is a Buy. Investors Observer’s proprietary rating system offers CDAK stock an average score of 35 out of 100.
What’s Happening to CDAK Stock Today
Codiak BioSciences Inc (CDAK) shares have risen 5.6 percent, as the S&P 500 has increased 1.65 percent at 3:26 pm on Friday Jan 20. CDAK has increased $0.03 from its trading price $0.58 with a volume of 76,977 shares. Over the past 12 months, the S&P 500 has declined by -11.59 percent, and CDAK was down -91.17 percent. CDAK was down -$0.68 per share during the last twelve months.
Codiak BioSciences Returns vs. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| CDAK | -91.20% | -95% | ||
| S&P | -13.98% | +38.73% | +6.76% | +12% |
Assets
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $51.76M | -47.5% |
| Accounts Receivable | $0.63M | -55.3% |
| Inventory | 0 | – |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $58.27M | -2.9% |
| Short Term Debt | $3.01M | +23.5% |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -11.9% | -77.7% |
| Return On Invested Capital | -93.9% | -14.0% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$9.45M | -38.3% |
| Operating Free Cash Flow | -$9.44M | -36.1% |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | 7.33 | 2.62 | 1.34 | 0.40 | -94.3% |
| Price to Sales | 10.87 | 6.27 | 1.87 | 0.59 | -97.3% |
| Price to Tangible Book Value | 7.33 | 2.62 | 1.34 | 0.40 | -94.3% |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | -15.33 | -20.44 | -14.22 | -1.87 | -88.6% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | -109.2% | -59.6% | -41.2% | -47.8% | – |
| Total Debt | $62.98M | $62.42M | $61.85M | $61.28M | -1.9% |
